UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 9, 2021

 

GENETHERA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-27237

 

65-0622463

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 3051 W 105th Ave. Westminster, CO

 

80031

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (720) 587-5100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

    

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12b of the act

 

Title of each Stocks

Trading Symbol 

Name of the Exchange which registered

Common Stocks

Preferred A

Preferred B

GTHR

OTCMK

 

Indicate by check mark whether the registrant is an emerging company as defined in Rule 405 of the Security act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act  of 1934 (240.12bof this chapter)

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting  standards provided pursuant to section 13(a) of the Exchange Act. ☐

 

 

 

 

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

GENETHERA, INC. AND CUSHMAN&WAKE FIELD ENTERED  INTO A  CONSULTING AGREEMENT

 

On September 9, 2021 GeneThera Inc. entered into a representation agreement with Cushman and Wakefield Us Inc. According to the terms on the agreement, Cushman and Wake field will represent GeneThera Inc in any transaction related to the acquisition of land in connection with to the construction of  GeneThera’s Biosafety Level 3 (BSL-3) laboratory facilities to be used as molecular robotic diagnostic therapeutic and research facilities for SARS-CoV-2 and other zoonotic diseases. Additionally Cushman & Wakefield will represent GeneThera in any transaction to secure warehouse space related to GeneThera assembly and storage of mobile laboratory units for the development of the wastewater surveillance network. Scope of the services and fees are outlined in Exhibit A attached to the Agreement. GeneThera Inc appoints Cushman & Wakefield as its sole agent and grants Cushman &Wakefield the exclusive right to represent GeneThera in any real estate transaction related to the Company Zoonotic Infectious Disease Alert Shield (ZIDAS) project.   

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibit Number

 

Description

 

 

 

10.1

 

Collaboration Agreement

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GeneThera, Inc.,

a Nevada Corporation

       
Date: October 12, 2021 By: /s/ Antonio Milici

 

 

Antonio Milici  
    CEO  

 

 
3

 

GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos GeneThera (CE).
GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos GeneThera (CE).